Dr. Backes on Safety Profile of Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

Floor J. Backes, MD
Published: Tuesday, Nov 12, 2019



Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses the safety profile from a phase I study looking at lenvatinib (Lenvima) and weekly paclitaxel in women with recurrent endometrial cancer.

The safety profile was typical for chemotherapy and included adverse events (AEs) such as cytopenia, lymphopenia, anemia, and some thrombocytopenia, but mostly the red and white cells were affected, explains Backes.

Additionally, toxicity was similar to other antivascular agents and included hypertension, mucositis, and nausea, says Backes. Hypertension was the most common grade 3 toxicity, but most AEs were grade 1/2. Overall, none of the AEs were unexpected, concludes Backes.
SELECTED
LANGUAGE


Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses the safety profile from a phase I study looking at lenvatinib (Lenvima) and weekly paclitaxel in women with recurrent endometrial cancer.

The safety profile was typical for chemotherapy and included adverse events (AEs) such as cytopenia, lymphopenia, anemia, and some thrombocytopenia, but mostly the red and white cells were affected, explains Backes.

Additionally, toxicity was similar to other antivascular agents and included hypertension, mucositis, and nausea, says Backes. Hypertension was the most common grade 3 toxicity, but most AEs were grade 1/2. Overall, none of the AEs were unexpected, concludes Backes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x